Literature DB >> 8938146

Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines.

D P Singal1, M Ye, X Qiu.   

Abstract

HLA class I molecules present antigenic peptides to cytotoxic T lymphocytes and thus play an important role in immune surveillance of cells infected with virus or altered by malignant transformation. Immunochemical studies have demonstrated a marked deficiency or lack of expression of class I molecules on the surface of many different types of tumor cells. It is likely that this allows these cells to escape immune surveillance. In the present study, we examined the molecular basis for lack of expression of class I antigens in small-cell lung carcinoma cell lines. Our results demonstrate that these cell lines also lacked products of MHC-encoded proteasome subunit LMP2 and the putative peptide transporter TAP1. In contrast, LMP7 and TAP2 genes were expressed in these cell lines. Pulse-chase experiments showed that class I molecules were unstable and thus not transported to the cell surface from endoplasmic reticulum. Our results suggest that antigenic peptides were not available for binding to class I alpha chains due to lack of TAP1 and LMP2 gene products. Investigations of the regulatory mechanisms of TAP1 and LMP2 genes showed that the tumor cells lacked trans -regulatory nuclear protein(s), which binds to the interferon-gamma (IFN-gamma) response element (ISRE) in the TAP1, LMP2 bidirectional intergenic promoter. Treatment of tumor cells with IFN-gamma induced ISRE-binding nuclear protein(s) and resulted in expression of TAP1 and LMP2 genes with a concomitant increase in cell-surface expression of class I molecules. Our data provide credence for a role of TAP and LMP genes in immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938146     DOI: 10.1002/(SICI)1097-0215(19961127)68:5<629::AID-IJC13>3.0.CO;2-X

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?

Authors:  Julie R Brahmer
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

2.  Major histocompatibility complex class I-restricted alloreactive CD4+ T cells.

Authors:  Louise H Boyle; Jane C Goodall; J S Hill Gaston
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

Review 3.  Why has active immunotherapy not worked in lung cancer?

Authors:  A Thomas; G Giaccone
Journal:  Ann Oncol       Date:  2015-07-30       Impact factor: 32.976

Review 4.  Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.

Authors:  Martin R Jadus; Josephine Natividad; Anthony Mai; Yi Ouyang; Nils Lambrecht; Sandor Szabo; Lisheng Ge; Neil Hoa; Maria G Dacosta-Iyer
Journal:  Clin Dev Immunol       Date:  2012-07-29

Review 5.  Cancer immunotherapy and nanomedicine.

Authors:  Wei-Yun Sheng; Leaf Huang
Journal:  Pharm Res       Date:  2010-09-04       Impact factor: 4.580

6.  Tumor Immune Microenvironment Characterization of Primary Lung Adenocarcinoma and Lymph Node Metastases.

Authors:  Yuan Zhou; Xinying Shi; Huan Chen; Beibei Mao; Xue Song; Lingling Gao; Jiao Zhang; Ying Yang; Henghui Zhang; Guo Wang; Wei Zhuang
Journal:  Biomed Res Int       Date:  2021-07-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.